Abstract: A new use of M-CSF or G-CSF for diagnosis or treatment of pulmonary fibrosis is disclosed. A marker for diagnosing the level of development or progression of pulmonary fibrosis contains M-CSF and/or G-CSF; and a composition for preventing or treating pulmonary fibrosis, contains an M-CSF inhibitor and a G-CSF inhibitor as active ingredients. The present inventors have ascertained that M-CSF and/or G-CSF is a marker for development or progression of pulmonary fibrosis, and have confirmed that a composition, which contains M-CSF and G-CSF and which binds to M-CSF and G-CSF so that the inherent mechanism thereof can be prevented, has an effect of significantly inhibiting myofibroblast hyperplasia or pulmonary fibrosis of the pulmonary cells, and thus the marker and the composition of the present disclosure are expected to be effectively usable for diagnosis, prevention or treatment of pulmonary fibrosis.

Abstract: A new use of M-CSF or G-CSF as a useful marker for diagnosis or treatment of pulmonary fibrosis is disclosed. Also disclose are a composition containing M-CSF inhibitor and/or G-CSF inhibitor, as active ingredients, wherein the composition is suitable for preventing or treating pulmonary fibrosis. A composition containing M-CSF inhibitor and/or G-CSF inhibitor which bind to M-CSF and G-CSF, respectively, has an effect of significantly inhibiting myofibroblast hyperplasia or pulmonary fibrosis of the pulmonary cells.

Abstract: The present invention relates to novel 2-Methoxyestradiol derivatives and their medical use. In particular, the novel derivatives of the present invention are useful for the treatment or prevention of liver or lung fibrosis. Accordingly, the present invention also provides medical uses of the 2-Methoxyestradiol derivatives of the present invention. The present invention also provides a method of treating or preventing liver or lung fibrosis comprising administering an effective amount of the 2-Methoxyestradiol derivatives of the present invention.

Abstract: A radiotherapy apparatus for an animal comprises a treatment part including an accommodation space for placing an animal, an irradiation part including an electron generator and a linear accelerator coupled to one side of the electron generator and disposed in a direction perpendicular to the treatment part, the linear accelerator being configured to emit radiation toward the treatment part, and an image acquisition part located at a preset interval from the treatment part along an irradiation direction of the radiation and configured to obtain an image of an irradiation area when the radiation is applied, wherein the radiation has an output of 1 MeV to 2 MeV so as to be applied to a diseased part located within a predetermined distance range from epidermis of the animal.

Abstract: A radiotherapy apparatus for an animal comprises a treatment part including an accommodation space for placing an animal, an irradiation part including an electron generator and a linear accelerator coupled to one side of the electron generator and disposed in a direction perpendicular to the treatment part, the linear accelerator being configured to emit radiation toward the treatment part, and an image acquisition part located at a preset interval from the treatment part along an irradiation direction of the radiation and configured to obtain an image of an irradiation area when the radiation is applied, wherein the radiation has an output of 1 MeV to 2 MeV so as to be applied to a diseased part located within a predetermined distance range from epidermis of the animal.

Abstract: A new use of M-CSF or G-CSF as a useful marker for diagnosis or treatment of pulmonary fibrosis is disclosed. Also disclose are a composition containing M-CSF inhibitor and/or G-CSF inhibitor, as active ingredients, wherein the composition is suitable for preventing or treating pulmonary fibrosis. A composition containing M-CSF inhibitor and/or G-CSF inhibitor which bind to M-CSF and G-CSF, respectively, has an effect of significantly inhibiting myofibroblast hyperplasia or pulmonary fibrosis of the pulmonary cells.

Abstract: The present disclosure relates to a composition of a complex comprising metformin and Chir99021 for treating fibrosis. The composition according to the present disclosure inhibits collagen deposition and inflammatory responses and prevents vascular fibrosis and tissue damage, thereby exhibiting excellent prevention and therapeutic effects against fibrosis.

Abstract: The present disclosure relates to a composite composition of 2-methoxyestradiol and Chir99021 for the treatment of fibrosis. The composition according to the present disclosure inhibits collagen deposition and inflammatory response, and prevents the fibrosis of blood vessels and tissue damage, and thus has excellent preventive and therapeutic effects on fibrosis.

Abstract: According to the present invention, disclosed is a radiotherapy apparatus for an animal, comprising: a treatment part including an accommodation space for placing an animal thereon; an irradiation part including an electron generator and a linear accelerator coupled to one side of the electron generator and placed in a direction perpendicular to the treatment part for emitting radiation toward the treatment part; and an image acquisition part, positioned at a predetermined interval with the treatment part along the direction of the emitting of radiation, for acquiring an image of an irradiation area when radiation is emitted, wherein an output of radiation is between 1 and 2 MeV so that radiation is emitted to an affected area positioned within a predetermined distance from the epidermis of the animal.

Abstract: The present invention relates to a pharmaceutical composition for radioprotection or radiomitigation with respect to radiation-induced damage, the composition comprising a compound of Formula 1, or a pharmaceutically acceptable salt thereof or a solvate thereof.

Abstract: The present invention relates to a pharmaceutical composition for radioprotection or radiomitigation with respect to radiation-induced damage, the composition comprising a compound of Formula 1, or a pharmaceutically acceptable salt thereof or a solvate thereof.

Abstract: The present invention provides a pharmaceutical composition for suppressing angiogenesis, containing heat shock protein 27 (HSP27) or a nucleic acid encoding HSP27. In addition, the present invention provides a pharmaceutical composition for treating cancer, containing HSP27 or a nucleic acid encoding HSP27. Additionally, the present invention provides a method of suppressing the in vitro growth of endothelial cells using HSP27. Further, the present invention provides a method of screening an active material for suppressing angiogenesis or an active material for treating cancer, comprising the following steps: processing endothelial cell lines into samples, respectively; measuring the content of HSP27 in an endothelial cell line; and selecting the sample in which the content of HSP27 in an endothelial cell line is increased compared with a control group.

Abstract: The present invention relates to a pharmaceutical composition for promoting angiogenesis, containing an antibody that specifically binds to heat shock protein (HSP) 27. In addition, the present invention relates to a pharmaceutical composition containing an antibody that specifically binds to HSP 27, for treating an angiogenesis-dependent ailment selected from a group consisting of a wound, chronic ulcer, ischemic stroke, myocardial infarction, angina pectoris, and cerebrovascular dementia. In addition, the present invention relates to a method for promoting the in vitro growth of endothelial cells using an antibody that specifically binds to HSP27.

Abstract: The present invention provides a pharmaceutical composition for suppressing angiogenesis, containing heat shock protein 27 (HSP27) or a nucleic acid encoding HSP27. In addition, the present invention provides a pharmaceutical composition for treating cancer, containing HSP27 or a nucleic acid encoding HSP27. Additionally, the present invention provides a method of suppressing the in vitro growth of endothelial cells using HSP27. Further, the present invention provides a method of screening an active material for suppressing angiogenesis or an active material for treating cancer, comprising the following steps: processing endothelial cell lines into samples, respectively; measuring the content of HSP27 in an endothelial cell line; and selecting the sample in which the content of HSP27 in an endothelial cell line is increased compared with a control group.

Abstract: The present invention relates to a pharmaceutical composition for promoting angiogenesis, containing an antibody that specifically binds to heat shock protein (HSP) 27. In addition, the present invention relates to a pharmaceutical composition containing an antibody that specifically binds to HSP 27, for treating an angiogenesis-dependent ailment selected from a group consisting of a wound, chronic ulcer, ischemic stroke, myocardial infarction, angina pectoris, and cerebrovascular dementia. In addition, the present invention relates to a method for promoting the in vitro growth of endothelial cells using an antibody that specifically binds to HSP27.

Abstract: A hard disk control module includes a load/unload counter and a controller. The load/unload counter counts a number of loads/unloads of a head on/from a surface of a disk. The controller may determine the number of counted loads/unloads during a reference time. The controller controls an unload standby time of the head according to a load/unload count value and the reference time.

Abstract: Background plasma electrons in a laser wake field are trapped and accelerated using a sharp downward density transition. A short and intense laser pulse travels through low density plasma with a sharp downward density transition. The density transition scale length is much smaller than the wavelength of a laser wake wave. As the laser wake wave passes the density transition, its wavelength increases suddenly so that some background plasma electrons are self-injected into the acceleration phase of the wake field and trapped and accelerated by the strong laser wake field.

Abstract: Background plasma electrons in a laser wake field are trapped and accelerated using a sharp downward density transition. A short and intense laser pulse travels through low density plasma with a sharp downward density transition. The density transition scale length is much smaller than the wavelength of a laser wake wave. As the laser wake wave passes the density transition, its wavelength increases suddenly so that some background plasma electrons are self-injected into the acceleration phase of the wake field and trapped and accelerated by the strong laser wake field.